Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

  title={Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients},
  author={Derick T. Wade and Petra Makela and Philip J. Robson and Heather House and Cynthia Bateman},
  journal={Multiple Sclerosis},
  pages={434 - 441}
The objective was to determine whether a cannabis-based medicinal extract (CBME) benefits a range of symptoms due to multiple sclerosis (MS). A parallel group, double-blind, randomized, placebo-controlled study was undertaken in three centres, recruiting 160 outpatients with MS experiencing significant problems from at least one of the following: spasticity, spasms, bladder problems, tremor or pain. The interventions were oromucosal sprays of matched placebo, or whole plant CBME containing… 

Figures and Tables from this paper

A Multicentre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Study of Effect of Long-Term Sativex Treatment on Cognition and Mood of Patients with Spasticity Due to Multiple Sclerosis
Long-term treatment with Sativex was not associated with cognitive decline or significant changes in mood in this prone population sample and no new safety concerns were identified.
Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.
In the first ever controlled trial of a CBM in RA, a significant analgesic effect was observed and disease activity was significantly suppressed following Sativex treatment.
Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis
It is concluded that this CBM may represent a useful new agent for treatment of the symptomatic relief of spasticity in MS.
The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms
Oromucosal spray and oral cannabis are mainly used for treating patients with MS and have positive effects on treating the most common symptoms of MS, such as pain and spasticity, whereas the other MS symptoms indicated slight improvement, for which further studies are needed.
Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis
It is concluded that long-term use of an oromucosal CBM (Sativex) maintains its effect in those patients who perceive initial benefit, and the precise nature and rate of risks with long- term use, especially epilepsy, will require larger and longer-term studies.
Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based Medicine
No tolerance to the benefit of Sativex on pain or sleep, nor need for dosage increases have been noted in safety extension studies of up to four years, wherein 40–50% of subjects attained good or very good sleep quality, a key source of disability in chronic pain syndromes that may contribute to patients' quality of life.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome.
Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach
There is no evidence to suggest that there was widespread unblinding to treatment allocation in these three studies of Sativex and Placebo, and this methodology may be suitable for assessment of the integrity of the blind in other randomized clinical trials.
The therapeutic value of cannabinoids in MS: real or imaginary?
This issue of Multiple Sclerosis contains three interesting papers that claim beneficial effects of cannabinoids on symptoms in MS patients. The randomized, double-blind, placebo-controlled,


A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms
Cannabis medicinal extracts can improve neurogenic symptoms unresponsive to standard treatments, and unwanted effects are predictable and generally well tolerated.
The perceived effects of smoked cannabis on patients with multiple sclerosis.
The survey findings will aid in the design of a clinical trial of cannabis or cannabinoid administration to MS patients or to other patients with similar signs or symptoms.
Safety, tolerability, and efficacy of orally administered cannabinoids in MS
Compared with placebo, neither THC nor plant-extract treatment reduced spasticity, and both THC and plant-Extract treatment worsened the participant’s global impression.
Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review
Cannabinoids are no more effective than codeine in controlling pain and have depressant effects on the central nervous system that limit their use, and in acute postoperative pain they should not be used.
Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.
There was significant improvement in patient ratings of spasticity compared to placebo at doses greater than 7.5 mg, suggesting a role for THC in the treatment ofSpasticity in multiple sclerosis.
Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?
Good evidence shows that secondary compounds in cannabis may enhance the beneficial effects of THC, and other cannabinoid and non-cannabinoid compounds in herbal cannabis or its extracts may reduce THC-induced anxiety, cholinergic deficits, and immunosuppression.
Cannabis as medicine: time for the phoenix to rise?
The BMA has addressed the question of scientific evidence that cannabis has real therapeutic value with an excellent report, which begins by reviewing the pharmacology.
Cannabinoids control spasticity and tremor in a multiple sclerosis model
It is shown that cannabinoid (CB) receptor agonism quantitatively ameliorated both tremor and spasticity in diseased mice, providing a rationale for patients' indications of the therapeutic potential of cannabis in the control of the symptoms of multiple sclerosis.
Prospects for New Cannabis-Based Prescription Medicines
A new generation of cannabis based medicinal products takes advantage of increasing understanding of the mode of action of cannabinoids, evidence-based research on clinical uses and new technology for realization of products, in anti-diversionary presenta...